Skip to main content
. 2017 Feb 2;76(8):1348–1356. doi: 10.1136/annrheumdis-2016-210246

Figure 1.

Figure 1

Patient disposition in the Certolizumab-Optimal Prevention of joint damage for Early rheumatoid arthritis trial. CZP, certolizumab pegol; FAS, full analysis set; MTX, methotrexate; PBO, placebo.